News
NTRA
126.97
+2.07%
2.58
How Is The Market Feeling About Natera?
Benzinga · 1d ago
Weekly Report: what happened at NTRA last week (1028-1101)?
Weekly Report · 3d ago
Press Release: Natera to Report its Third Quarter 2024 Results on November 12, 2024
Dow Jones · 5d ago
Natera And GeneDx: Outperforming Market Powered By Precision Medicines Tailwinds
Seeking Alpha · 6d ago
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500
Benzinga · 6d ago
Natera Is Maintained at Outperform by Bernstein
Dow Jones · 10/30 19:09
Bernstein Maintains Outperform on Natera, Raises Price Target to $135
Benzinga · 10/30 18:59
NATERA INC <NTRA.O>: BERNSTEIN RAISES TARGET PRICE TO $135 FROM $125
Reuters · 10/30 10:54
Natera price target raised to $135 from $125 at Bernstein
TipRanks · 10/30 10:36
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
NASDAQ · 10/30 10:20
U.S. RESEARCH ROUNDUP-Agilon Health, Alphabet, Crocs
Reuters · 10/30 06:34
Tempus: Attempting To Lead The AI Revolution In Healthcare
Seeking Alpha · 10/29 17:47
Natera Is Maintained at Buy by Canaccord Genuity
Dow Jones · 10/29 12:31
Natera Price Target Raised to $150.00/Share From $145.00 by Canaccord Genuity
Dow Jones · 10/29 12:31
Canaccord Genuity Maintains Buy on Natera, Raises Price Target to $150
Benzinga · 10/29 12:21
Natera price target raised to $150 from $145 at Canaccord
TipRanks · 10/29 11:01
U.S. RESEARCH ROUNDUP- Coinbase Global, Meta, Union Pacific
Reuters · 10/29 06:41
Weekly Report: what happened at NTRA last week (1021-1025)?
Weekly Report · 10/28 09:25
Natera: A Genetic Investment Worth Watching And Holding
Seeking Alpha · 10/27 09:54
Artisan Global Equity Fund Q3 2024 Commentary
Seeking Alpha · 10/25 14:30
More
Webull provides a variety of real-time NTRA stock news. You can receive the latest news about Natera Inc through multiple platforms. This information may help you make smarter investment decisions.
About NTRA
Natera, Inc. is a diagnostics company, which is focused on the development and commercialization of molecular testing services, applying its technology in the fields of women’s health, oncology and organ health. Its cell-free deoxyribonucleic acid (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening, Spectrum Preimplantation Genetics, Anora Miscarriage Test, Empower, and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Company’s algorithms and bioinformatics in order to validate and launch tests based on the Company’s technology. Its NIPT screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother.